Sponsors (30)
Official title: To expand research, improve awareness, and increase access to treatment for individuals affected by Premenstrual Dysphoric Disorder, and for other purposes.
Introduced March 30, 2026 by Yassamin Ansari · Last progress March 30, 2026
The bill aims to improve recognition, research, and care for PMDD—strengthening clinician training and data collection and reducing stigma—but does so through open‑ended authorizations that may increase federal spending, risk uneven implementation, and may not deliver prompt, equitable benefits unless appropriations and inclusive execution follow.
Women and people with PMDD (and other affected patients) would gain better diagnosis, treatment, and access to care because the bill promotes awareness, research, education, and care expansion.
Clinicians, trainees, and health systems would receive expanded training (CME, residency/fellowship support, curricular materials), strengthening workforce capacity to recognize and manage PMDD and related mid-life women’s health issues.
Federal-funded research and reporting would increase knowledge about PMDD (including requirements for diverse representation), producing more effective, inclusive diagnostics and treatments over time.
Taxpayers could face significant additional federal spending because the bill repeatedly authorizes open-ended amounts ('such sums as necessary') across multiple fiscal years without a specified cap.
Findings and authorizations do not guarantee appropriations — awareness, reports, or program designs could exist on paper without funding, so promised research, education, and access improvements may not materialize.
Research, reporting, and program development will take years to affect clinical practice; patients may not see immediate treatment improvements and some stakeholders may delay action pending reports.
Based on analysis of 6 sections of legislative text.
Expands federal PMDD research and data collection, funds public awareness and provider education, creates grants for training, and requires a progress report to Congress.
Requires the Department of Health and Human Services, through NIH and HRSA, to expand and intensify research on Premenstrual Dysphoric Disorder (PMDD), run a public awareness campaign, develop provider training and continuing medical education, and award grants to expand clinical training and services. It directs HHS to collect and publish prevalence and impact data, authorizes appropriations for multiple fiscal years, and requires a progress report to Congress within two years.